Phenylacetylglutamine
metabolitePAGln derived from microbiota metabolism promotes platelet activation and thrombotic response, increasing MI risk in rupture-prone plaques.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencehigh
RationaleGut metabolite enhances platelet responsiveness; associated with plaque rupture and thrombosis.
Also acts inMyocardial injury
Druggability
Not assessed (no mapped human gene target).
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(4)
- Comprehensive age-specific metabolic phenotyping in myocardial infarction.BMC cardiovascular disorders · 2026 · PMID 41654757 · doi
- Association between Intestinal Flora Metabolites and Coronary Artery Vulnerable Plaque Characteristics in Coronary Heart Disease.British journal of hospital medicine (London, England : 2005) · 2025 · PMID 40135300 · doi
- Phenylacetyl glutamine (PAGln) enhances cardiomyocyte death after myocardial infarction through β1 adrenergic receptor.Environmental toxicology · 2023 · PMID 38041472 · doi
- A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors.Cell · 2020 · PMID 32142679 · doi